0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Notice to Readers: Revised Definition of Extensively Drug-Resistant Tuberculosis FREE

JAMA. 2006;296(23):2792. doi:10.1001/jama.296.23.2792-a.
Text Size: A A A
Published online

MMWR. 2006;55:1176

In a report published on March 24, 2006, MMWR reported that CDC, in collaboration with the World Health Organization (WHO) and participating supranational reference laboratories, had agreed to define extensively drug-resistant tuberculosis (XDR TB) as cases of TB disease in persons whose Mycobacterium tuberculosis isolates were resistant to isoniazid and rifampin and at least three of the six main classes of second-line drugs (aminoglycosides, polypeptides, fluoroquinolones, thioamides, cycloserine, and para-aminosalicyclic acid).1 Since that original publication, additional reports have documented the presence of XDR TB in Iran and South Africa with high mortality among persons infected with human immunodeficiency virus (HIV) who are benefiting from antiretroviral therapy.2,3

The emergence and transmission of these strains of M. tuberculosis highlight the urgency of strengthening national TB and HIV/acquired immunodeficiency syndrome control programs worldwide, particularly in settings with high HIV prevalence. CDC is collaborating with national and international health agencies to provide leadership, technical support, and capacity building to ensure proper action is taken to limit the development and spread of XDR TB. An initial consultation was convened by the South Africa Medical Research Council in Johannesburg, South Africa, during September 6-7, 2006. A seven-point emergency action plan to combat XDR TB was issued by agencies represented at this meeting (additional information is available at http://www.mrc.ac.za/pressreleases/8pres2006.htm). Subsequently, WHO organized the first meeting of the Global XDR TB Task Force, held in Geneva, Switzerland, during October 8-9, 2006. This meeting was called by WHO to develop a rapid response to the emerging problem of XDR TB. As a result of the meeting, participants agreed upon a revised case definition of XDR TB. According to laboratory professionals in attendance, drug-susceptibility testing to fluoroquinolones and second-line injectable drugs (i.e., amikacin [aminoglycoside], kanamycin [aminoglycoside], or capreomycin [polypeptide]) yields reproducible and reliable results, whereas drug-susceptibility testing to other second-line drugs is less reliable. Additionally, investigators have observed that resistance to these drugs (fluoroquinolones and second-line injectable drugs) has been associated with poor treatment outcomes. Accordingly, the new agreed-upon definition of XDR TB is the occurrence of TB in persons whose M. tuberculosis isolates are resistant to isoniazid and rifampin plus resistant to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).

Health-care providers and local health departments in the United States should collect all second-line drug-susceptibility results obtained at diagnosis and during treatment of persons with TB disease and report these results to their local and state health department TB programs. Complete capture of these results will allow health departments and CDC to accurately identify XDR TB cases and monitor trends. Additional information about XDR TB is available at http://www.who.int/tb/en.

REFERENCES
CDC.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000-2004.  MMWR. 2006;55:301-305
Masjedi MR, Farnia P, Sorooch S.  et al.  Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran.  Clin Infect Dis. 2006;43:841-847
PubMed   |  Link to Article
Gandhi NR, Moll A, Sturm AW.  et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.  Lancet2006;(October):26 http://www.thelancet.com/journals/lancet/article/PIIS0140673606695731. Online
PubMed

Figures

Tables

References

CDC.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000-2004.  MMWR. 2006;55:301-305
Masjedi MR, Farnia P, Sorooch S.  et al.  Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran.  Clin Infect Dis. 2006;43:841-847
PubMed   |  Link to Article
Gandhi NR, Moll A, Sturm AW.  et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.  Lancet2006;(October):26 http://www.thelancet.com/journals/lancet/article/PIIS0140673606695731. Online
PubMed

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

* * SCHEDULED MAINTENANCE * *

Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles